Investigational Therapy for Type 1 Diabetes

The VX22-264-101 Study is looking for individuals living with type 1 diabetes (T1D) to participate in a study of an investigational therapy called VX-264. VX-264 is designed to produce insulin contained within investigational devices implanted in the space behind the muscles of the abdominal wall. Researchers are studying the safety, tolerability, and effectiveness of VX-264 in adults with T1D and are looking to see if it could potentially reduce or eliminate the need for individuals with T1D to take insulin.

See if you may qualify

This clinical study is currently enrolling adults between the ages of 18 and 65 who have type 1 diabetes and require insulin via injections or pump to manage their diabetes. If you are interested in taking part in this clinical research study, please continue below and complete the questionnaire to determine if you are a good candidate and eligible for participation.

Learn more about this clinical study.

See If You May Qualify

Step 1 of 3

By answering the following prescreening questions, you agree to provide your information to Praxis, a service provider of the sponsor of this study, Vertex Pharmaceuticals Incorporated (Vertex). The categories of information collected via this questionnaire include: your name and contact information, information about your health and lifestyle, and any other information that you provide. Your information will be used only to determine whether you are eligible for this research study and, if you consent, to inform you of potential Vertex research studies in the future. It will not be shared with Vertex in any way that could identify you. You will also have the option to delete the information after you complete the prescreening process.

If your answers to the questionnaire indicate you may be eligible for the study and you elect to share your contact information, Praxis (we) will share your information with Circuit Clinical, who is also a service provider to Vertex on this study, and who will contact you to do a full prescreening. Based on the results of that screening, and with your permission, your information would be shared with a research site. We will not share your personal information with anyone outside of this study other than as required by law, and we will not sell personal information collected from you as part of this study screening. If you are not found to be eligible for this study, you will have the option for Praxis to keep your information on file for a period of time that you elect so you can be contacted if the eligibility criteria change for the VX22-264-101 Study and/or future Vertex studies.

For a fuller description of Vertex’s privacy practices, and of your privacy rights if you are a California resident, please see Vertex’s privacy notice.

If you have a question or want to exercise your privacy rights detailed in the above privacy notice, please contact Praxis at legal@gopraxis.com, as Vertex will not receive your identifiable information.

Do you agree to submit your information?

e.g., 12345

YYYY

This website uses Secure Socket Layer technology and encryption methods to protect personal health information.